ROTH Capital Partners to Sponsor & Speak at BIO CEO Conference

Published : Wednesday, February 5, 2020, 6:00 am
ACROFAN=Business Wire | | SNS

Yasmeen Rahimi, PhD, to speak on NASH and other new Liver Treatments

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (“ROTH”), a full service investment bank focused on advising and financing growth companies, is pleased to announce its participation as a sponsor and panelist at the BIO CEO & Investor Conference on February 10-11, 2020 in New York City.

Yasmeen Rahimi, PhD – Managing Director, Senior Research Analyst, and Co-head of Biotechnology Research – is on the 2020 Program Advisory Committee as well as the Moderator for the Preparing for NASH and Other New Liver Treatments panel taking place 1:30 PM - 2:25 PM, Monday, February 10, 2020 ・ Lyceum Complex at the New York Marriott Marquis.

With 2019 in the books and the first FDA approval of a NASH therapeutic potentially months away, this panel will bring together a group of industry insiders to offer a look back at the clinical progress gained in the past year while also looking ahead to topics that will dominate attention in the NASH space in 2020, including what the ideal anti-fibrotic approaches are for F4 cirrhotic patients, input from regulators regarding biopsy-required label, and the optimal road ahead as companies approach commercialization and reimbursement questions for this brand new therapeutic frontier. The attendees will hear from a distinguished panel that includes Mark Pruzanski, President and CEO of Intercept Pharmaceuticals, Pascal Prigent, CEO of Genfit S.A., David Woodhouse, CEO and Acting Financial Officer of NGM Bio, Morris Birnbaum, Senior Vice President and Chief Scientific Officer for the Internal Medicine Research Unit at Pfizer, Scott Friedman, Chief of the Division of Liver Disease at Icahn School of Medicine Mount Sinai, and Roger Green, CEO of RG&A Consulting.

Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Experience the best of biotech with two days of productive partnering meetings with institutional investors, industry analysts, and senior biotechnology executives, in one location. To register and for more information about the BIO CEO & Investor Conference -

Since 2010, ROTH has completed over 460 healthcare transactions, raising approximately $18.5 billion for its clients. (Source – ROTH – 02/03/2020)

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.

Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit


Investor and Media Contact:
ROTH Capital Partners
Isabel Mattson-Pain
Director of Marketing, - 949-720-7117

Copyright © acrofan/Business Wire All Right Reserved

    Acrofan     |     Contact Us :     |     Contents API : RSS

Copyright © Acrofan All Right Reserved